A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of Neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction: 6-month outcomes
The Journal of Heart and Lung Transplantation（2005）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要